$MRNA: Moderna Just Made History Twice. Now the Market Has to Decide What It's Worth.
In two weeks, Moderna got the first mRNA flu vaccine approved in U.S. history and won the first successful Phase 3 for a personalized cancer vaccine. The stock moved 177% in a day. Here's what it's worth.
At the open on August 20, 2026, Moderna's stock was trading around $62.96. By mid-session it was approaching $174. That is a 177% one-session move -- one of the largest single-day gains in the company's public history -- and it pushed MRNA to within a fraction of its 52-week high of $176.66.
Two things caused it. Both of them had never happened before.
History Event One: The First mRNA Flu Vaccine
On August 5, the FDA approved mFLUSIVA -- the first mRNA-based influenza vaccine ever authorized for use in the United States. The milestone carries real scientific weight. mRNA vaccine technology has been deployed against COVID-19 at a scale that rewrote the trajectory of a pandemic, but the flu vaccine market -- a $6-plus billion annual business built on decades of egg-based and recombinant manufacturing -- has resisted disruption. Until now.
The approval is anchored in the FLUENT trial, which enrolled 40,805 adults and met every primary endpoint. Against the standard-dose seasonal flu shot, mFLUSIVA delivered 26.6% better relative vaccine efficacy -- rising to 27.4% in adults 65 and older. The FDA granted full approval for adults 50-64 and accelerated approval for adults 65 and older, with a confirmatory study required to complete the older-age label. Regulatory reviews are underway in the EU, Canada, and Australia. Commercial launch is targeted for the 2026-27 flu season.
For the first time in more than 70 years of seasonal flu vaccination in America, the dominant platform technology is not eggs.
History Event Two: The First Successful Phase 3 for a Personalized Cancer Vaccine
The second milestone landed on August 20 itself, which is why the stock moved 177% today rather than the 20-30% it moved after the mFLUSIVA approval.
Moderna announced that INTerpath-001 -- its personalized mRNA cancer vaccine, built individually for each patient from sequenced tumor mutations -- met the primary endpoint of a Phase 3 trial in resected melanoma. The trial enrolled 1,137 patients with Stage IIB-IV completely resected melanoma who had received no prior systemic therapy. They were randomized 2:1: intismeran autogene (the personalized vaccine) plus Pembrolizumab (Merck's Keytruda) versus Keytruda alone. The primary endpoint -- Recurrence-Free Survival -- was statistically significant. The key secondary endpoint -- Distant Metastasis-Free Survival -- was also statistically significant. Overall Survival data is still maturing.
Moderna has not yet released the specific hazard ratios. Full data will be presented at an upcoming medical conference. What they have confirmed is the headline: a Phase 3 randomized controlled trial just showed that a cancer vaccine improves outcomes in a statistically meaningful way.
This is the first time that sentence has been true, for any personalized mRNA cancer vaccine, anywhere in the world.
The Setup That Got Here
The Phase 3 result did not arrive without precedent. The Phase 2b trial -- KEYNOTE-942 -- had already been running for years, and its five-year data showed an HR of 0.51 for Recurrence-Free Survival (a 49% risk reduction versus Keytruda alone) and an HR of 0.411 for Distant Metastasis-Free Survival (a 59% risk reduction). Those numbers turned the scientific community's skepticism about personalized cancer vaccines into cautious optimism. The Phase 3 just confirmed that those results held -- and held at scale, in a trial more than twice as large.
Merck paid a $250 million option fee in 2022 to collaborate on this platform. The economics are structured as a 50/50 cost and profit split. Merck's Keytruda franchise generated over $25 billion in revenue in 2025. Its interest in this collaboration is not casual.
The Market's Calculation
Here is the arithmetic the market ran today. Moderna is now valued at approximately $69.62 billion at $174 per share, on roughly 400 million shares outstanding. The company reported $2.23 billion in trailing twelve-month revenue, down 27.6% year-over-year. Its trailing net loss is $3.15 billion. Its stated target is cash flow break-even by 2028.
The market has decided, in one session, that those fundamentals are underpriced given what the pipeline just proved. Whether that calculation holds tomorrow -- and what the stock is actually worth at this price -- is the question paid members are about to read.
The rest of this briefing is for paid members: the balance sheet clock (how much runway Moderna actually has), the mFLUSIVA commercial timing problem analysts are already pricing in, what a 50/50 Merck split means for Moderna's cancer vaccine upside, the scenario-by-scenario price framework, and the one upcoming catalyst date that resets the whole thesis.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish -- the analysis private intel clients pay four figures for, at a fraction of that.